Summit Therapeutics Announces $2B AstraZeneca Equity Investment and Ivonescimab Clinical Collaboration

Summit received a $2B strategic equity investment from AstraZeneca in convertible preferred shares at $18.36 per common share equivalent. Summit entered a clinical trial collaboration to evaluate ivonescimab plus AstraZeneca's sonesitatug vedotin (sone-ve) in GI cancers, with plans for additional combinations of ivonescimab with AstraZeneca ADCs and other oncology medicines; each party retains rights to their molecules and shares study costs.

Key facts

Filed: Sep 29, 2026, 01:39 AM
Event: Partnership / licensing deal
Direction: Positive
Company: SMMTSummit Therapeutics
Asset: ivonescimab
Source: SEC 8-K
Confidence: Sourced
investment: $2.0 billion
conversion price: $18.36

Source excerpt

AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics Investment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit’s Common Stock of $18.36, Representing a Premium over Today’s Closing Trading Price Summit Also Enters into Clinical Trial Collaboration with AstraZeneca to Evaluate Ivonescimab in Combination with Sonesitatug Vedotin in Multiple Gastrointestinal Cancers Summit & AstraZeneca Plan to Enter into a Clinical Trial Collaboration Combining Ivonescimab with Multiple AstraZeneca ADCs and Other Cancer Medicines Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve). Moreover, Summit and AstraZeneca intend to evaluate ivonescimab with an additional set of AstraZeneca’s cancer medicines, including other antibody drug conjugates (ADCs). Ivonescimab is a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. AstraZeneca Equity Investment in Summit Summit an

SEC 8-K